The biotech and pharma industries are rapidly evolving, with mergers and acquisitions driving innovation and growth. As market demands shift, these deals reshape strategies, bolster R&D, and bring groundbreaking therapies to healthcare.
With over 35 years of experience, Stephen Sands has guided high-impact transactions that have shaped the biotech and pharma landscape. In this episode, Janice Bourque speaks with Stephen about his journey from bioengineer to healthcare M&A leader. They examine the forces that drive today’s major deals, from global expansion to complex valuation challenges, and the strategies that ensure success in a competitive market.
Topics Include:
Key trends and strategies in biotech/pharma M&A
Challenges in valuing early-stage biotech companies
Pharma’s evolving role in funding and scaling biotech innovations
Future outlook for healthcare partnerships and acquisitions
Stephen’s insights on the future of healthcare M&A
And other topics…
Stephen Sands is a Senior Advisor in Lazard’s Global Healthcare Group with a distinguished career in healthcare M&A. Known for his expertise in biotech and pharma, Stephen has led some of the industry's most transformative transactions, helping to drive strategic growth and innovation in the healthcare sector.
This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.
Podden och tillhörande omslagsbild på den här sidan tillhör
Hercules Capital. Innehållet i podden är skapat av Hercules Capital och inte av,
eller tillsammans med, Poddtoppen.
